

Metal-Free Synthesis of *N*-Aryl-Substituted Azacycles from Cyclic Ethers using POCl

Minh Thanh La, Soosung Kang, and Hee-Kwon Kim

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.9b00377 • Publication Date (Web): 30 Apr 2019

Downloaded from <http://pubs.acs.org> on May 1, 2019

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3
4 **Metal-Free Synthesis of *N*-Aryl-Substituted Azacycles from**
5
6
7 **Cyclic Ethers using POCl₃**
8
9

10
11
12
13 Minh Thanh La[†], Soosung Kang[§], and Hee-Kwon Kim^{*,†,‡}
14
15

16
17
18 [†]Department of Nuclear Medicine, Molecular Imaging & Therapeutic Medicine Research Center,
19
20 Chonbuk National University Medical School and Hospital, Jeonju, 54907, Republic of Korea
21

22
23 [‡]Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research
24
25 Institute of Chonbuk National University Hospital, Jeonju, 54907, Republic of Korea
26

27
28 [§]College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans
29
30 University, Seoul 03760, Republic of Korea
31
32


33
34
35
36
37
38
39
40 Corresponding author: Hee-Kwon Kim.
41

42
43 * Corresponding author.
44

45
46 Tel: +82 63 250 2768; Fax: +82 63 255 1172.
47

48
49 *E-mail address:* hkkim717@jbnu.ac.kr (H-K Kim).
50
51
52
53
54
55
56
57
58
59
60

GRAPHICAL ABSTRACT



ABSTRACT

A facile method for the synthesis of *N*-aryl substituted azacycles from arylamines and cyclic ethers has been developed. In this study, arylamines were treated with cyclic ethers in the presence of POCl_3 and DBU to provide five- and six-membered azacycles. Using this method, various azacycloalkanes, isoindolines, and tetrahydroisoquinolines were prepared in high yields. This synthetic method offers an efficient approach to the production of azacycles from cyclic ethers.

INTRODUCTION

The development of novel synthetic methods for *N*-substituted azacycles is an important topic in organic and medicinal chemistry; this is because these motifs possess valuable properties as building blocks for structures of complex biomolecules, and *N*-substituted azacycles are present in many pharmaceuticals as well as organic materials.¹ Thus, azacycle structures have received much attention in the drug discovery and materials industries. In particular, it was reported that several novel drugs recently approved by the FDA contain an *N*-substituted azacycle moiety (Figure 1).²





Figure 1. FDA approved drugs containing azacycles

Due to a variety of applications involving azacycle structures, several synthetic methods were reported to prepare *N*-substituted azacycle compounds: the reaction of primary arylamines with dihalides or diols,³ reduction of tertiary lactams or azacyclobutenes formed by cyclocondensation between dicarbonyl compounds and an amine,⁴ and a cross-coupling reaction of *N*-unsubstituted azacycles and aryl halides.⁵ An intramolecular C(sp³)-N coupling reaction was also reported to prepare *N*-substituted azacycles.⁶ The reaction of a primary amine with cyclic ethers to prepare azacycles is an attractive method, as water is the co-product formed during condensation. Several protocols using arylamines and cyclic ethers have been described; the first method to synthesize *N*-phenylpyrrolidine was the reaction of tetrahydrofuran and aniline, using activated alumina at 400 °C.⁷ Other metal-based approaches have been utilized for the synthesis of *N*-substituted


azacycles, including Al_2O_3 , AlCl_3 , TiCl_4 or AlMe_3 .⁸ Recently, several methods were developed using non-metal catalysts. Zhang and co-workers employed $\text{B}(\text{C}_6\text{F}_5)_3$ and $p\text{TSA}\cdot\text{H}_2\text{O}$ to synthesize *N*-substituted azacycles via a frustrated Lewis pairs pathway.⁹ Other metal-free protocols using HI or $\text{BF}_3\cdot\text{Et}_2\text{O}$ were also developed.¹⁰ However, these methods employ acid or Lewis acid catalysts that may be incompatible with acid-sensitive functional groups. To overcome the issues of previously reported azacycle syntheses, herein we report a metal-free and efficient base-mediated synthesis of five- or six-membered ring azacycle compounds (Scheme 1).

Previous studies:

- *N,N*-dialkylation of arylamine using dihalides or diol




- Metal-based *N*-hetero-cyclization of arylamine



metal-based reagents = Al_2O_3 , AlCl_3 , TiO_2 , TiCl_4 , AlMe_3


- Metal-free *N*-hetero-cyclization of arylamine in acidic condition



reagents = $\text{B}(\text{C}_6\text{F}_5)_3$ in $p\text{TSA}\cdot\text{H}_2\text{O}$, HI

This work:

Metal-free *N*-hetero-cyclization of arylamine




Scheme 1. Synthesis of *N*-substituted azacycles.

RESULTS AND DISCUSSION

Synthetic chemistry of target products utilizing metal-free methods is a highly desirable green methodology. For the development of a novel metal-free reaction, phosphoramidates can be attractive intermediates for the preparation of target products since they are known precursors that have been practically used to synthesize amines, imines, and heterocycles such as aziridines.¹¹ Thus, we envisioned that a synthesis of azacycles utilizing phosphoramidic dichloride intermediates starting from amines would be realizable, and we hypothesized that reactions of amines with POCl₃ could be employed for *in situ* generation of phosphoramidic dichloride, which are active intermediates leading to azacycles. Such utilization of this base reaction system could be a novel approach to prepare *N*-unsubstituted azacycles. To test our hypothesis, aniline was selected as a model substrate in the initial study. Reaction with tetrahydrofuran (THF) was performed in xylene at 110 °C for 15 h, and the yield of the corresponding azacycle was investigated. First, reactions with a series of Lewis acids including CuCl₂, FeCl₃, ZnCl₂, ZrCl₄, and BiCl₂ were surveyed. However, the product was not obtained in most of the experiments (Table 1). When SnCl₂ was employed, the product was obtained in low yield. In addition, treatment with CaI₂, or CaBr₂ did not produce the azacycle. In this study, POCl₃ were employed for the synthesis of *N*-aryl substituted azacycle, and it was found that the reaction with POCl₃ provided the target azacycle with an improved yield (35%). Next, we investigated the base effect on the synthesis of *N*-substituted azacycles. Employment of K₂CO₃, NaHCO₃, triethylamine, 4-dimethylaminopyridine (DMAP), KOH, and NaOH resulted in low yields of azacycles. When Cs₂CO₃ was used as a base, the yield of azacycle increased to 70%, but was still unsatisfactory. However, when DBU was used in the reaction, the desired azacycle was prepared in significantly increased yield (95%). Screening of solvents was also performed to

further optimize the reaction conditions. Reactions in MeCN, DMF, and DCE resulted in no reaction. When toluene and PhCF₃ were used as the reaction solvent, the yield of the azacycle was enhanced to 44% and 45%, respectively. When xylene was employed in the reaction, the yield of the corresponding azacycle increased significantly (95%).

Table 1. Screening of reaction conditions for the preparation of azacycles^a.



Entry	Reagents	Base	Solvent	Yield ^b (%)
1	CuCl ₂	-	xylene	NR ^c
2	FeCl ₃	-	xylene	NR ^c
3	ZnCl ₂	-	xylene	NR ^c
4	ZrCl ₄	-	xylene	NR ^c
5	BiCl ₂	-	xylene	NR ^c
6	MnCl ₂	-	xylene	NR ^c
7	SnCl ₂	-	xylene	24
8	CaI ₂	-	xylene	NR ^c
9	CaBr ₂	-	xylene	NR ^c
10	POCl ₃	-	xylene	35
11	POCl ₃	K ₂ CO ₃	xylene	44
12	POCl ₃	CsCO ₃	xylene	70
13	POCl ₃	NaHCO ₃	xylene	41
14	POCl ₃	Et ₃ N	xylene	42

15	POCl ₃	DMAP	xylene	NR ^c
16	POCl ₃	KOH	xylene	23
17	POCl ₃	NaOH	xylene	22
18	POCl ₃	DBU	xylene	95
19	POCl ₃	DBU	toluene	44
20	POCl ₃	DBU	PhCF ₃	45
21	POCl ₃	DBU	MeCN	NR ^c
22	POCl ₃	DBU	DMF	NR ^c
23	POCl ₃	DBU	DCE	NR ^c
24 ^d	POCl ₃	DBU	xylene	91
25 ^e	POCl ₃	DBU	xylene	88


^a Reaction conditions: compound **1a** (1 mmol), THF **2a** (20 mmol), reagents (1.5 mmol), Base (2 mmol), solvent (3 mL), 110 °C, 15 h; ^b Isolated yield after purification of flash column chromatography; ^c No reaction; ^d compound **1a** (1 mmol), THF **2a** (10 mmol), POCl₃ (1.5 mmol), DBU (2 mmol), xylene (3 mL), 110 °C, 15 h; ^e compound **1a** (1 mmol), THF **2a** (5 mmol), POCl₃ (1.5 mmol), DBU (2 mmol), xylene (3 mL), 110 °C, 15 h

To better understand the effect of reagents and base on the reaction, reactions of aniline with a series of equivalents of POCl₃ and DBU were performed to produce the desired azacycle (see Table S1 in supporting information). The reaction results indicated that the highest yield of azacycle was observed in the presence of 1.5 equiv. of POCl₃ and 2.0 equiv. of DBU (95%), but

1
2
3
4 further addition of POCl₃ and DBU did not enhance the yield. In addition, we further investigated
5
6 the use of different amounts of THF in the synthesis of azacycle. The yield of azacycle product
7
8 increased in proportion to the amount of reagent (88% for 5 equiv. of THF and 91% for 10 equiv.
9
10 of THF). In particular, employment of 20 equiv. of THF produced the target azacycle in high
11
12 yield, although there was no significant difference in yield between employment of 20 equiv., 30
13
14 equiv., and 40 equiv. of THF.
15
16





17
18 With optimized reaction conditions in hand, the scope of this protocol for the synthesis of
19
20 azacycles from arylamines and cyclic ethers was explored (Scheme 2). Most of the target
21
22 azacycles were prepared in high yields via treatment of various arylamines with cyclic ethers.
23
24 The synthesis of azacycles from arylamines and cyclic ethers was not significantly influenced by
25
26 the electronic properties of substituents on the aromatic ring. Arylamines bearing electron-
27
28 donating groups (methyl-, methoxyl-) and electron-withdrawing groups (nitro-, chloro-, fluoro-)
29
30 reacted well with cyclic ethers under the optimal reaction conditions, yielding the desired *N*-aryl-
31
32 substituted azacycles in high yields (Scheme 2, **3b-j**). Naphthylamine, 3,4-
33
34 (methylenedioxy)amine, and 1,4-benzodioxan-6-amine were also employed with
35
36 tetrahydrofuran, affording the corresponding azacycles in 92%, 82%, and 80% yield,
37
38 respectively (Scheme 2, **3k-m**). Besides, *N,N*-dimethyl-*p*-phenylenediamine bearing a nitrogen
39
40 and 2-aminopyridine, a heterocyclic amine, were used with tetrahydrofuran, yielding the
41
42 corresponding azacycles in 76%, and 55% yield, respectively (Scheme 2, **3n-o**). It was
43
44 noteworthy that mono-substitution of the aniline such as *p-t*-Bu-substituted arylamine did not
45
46 result in a big difference from that of aniline in the reaction. However, the reaction of 3,5- and
47
48 2,6-disubstituted anilines provided the desired products in lower yields (Scheme 2, **3e-f**). The
49
50 tolerance of different cyclic ethers was also explored. Even though 2-methyltetrahydrofuran is
51
52
53
54
55
56
57
58
59
60

1
2
3
4 more sterically hindered than THF, it successfully reacted with various aryl amines (such as
5
6 aniline, amines containing electron-donating and electron-withdrawing groups, and
7
8 naphthylamine) to yield the corresponding products in high yields (Scheme 2, **3p-s**). In addition,
9
10 tetrahydropyran, a six-membered cyclic ether, and oxepane, a seven-membered cyclic ether,
11
12 were employed for the synthesis of azacycles, and the yields were somewhat lower (Scheme 2,
13
14 **3t-u**). 1,4-Dioxane, a heterocyclic compounds, was also used to react with tetrahydrofuran,
15
16 giving the corresponding azacycles in 57% yield (Scheme 2, **3v**).
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Scheme 2. Scope of synthesis of azacycloalkanes^a

^a Reaction conditions: compound **1** (1 mmol), cyclic ethers **2** (20 mmol), POCl₃ (1.5 mmol), DBU (2 mmol), xylene (3 mL), 110 °C, 15 h


1
2
3
4 From these positive synthesis results, the scope of utilizing POCl₃ was extended to the synthesis
5 of nitrogen-containing fused heterocyclic ring materials from arylamines. In particular,
6 tetrahydroisoquinolines and isoindolines are important azacycle motifs in many biological active
7 pharmaceuticals and natural products.¹² The treatment of aniline with phthalan readily resulted in
8 successful synthesis of the corresponding azacycle in 93% yield (Scheme 3, **5a**). Furthermore,
9 the electronic effect of substituents on the aryl amine was not significantly different from those
10 shown in Scheme 3. The reaction of various arylamines bearing electron-donating groups or
11 electron-withdrawing groups with phthalan also produced the corresponding isoindolines in
12 satisfactory yields (Scheme 3, **5b-e**). In addition, the reaction of arylamines with isochroman
13 under the same reaction conditions produced tetrahydroisoquinolines in high yields (Scheme 3,
14 **5f-i**). These results suggest that POCl₃ and DBU could serve as an important reagent combination
15 for the efficient conversion of arylamines to *N*-aryl substituted five- and six-membered
16 azacycles.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Scheme 3. Scope of synthesis of isoindolines and tetrahydroisoquinolines^a**5a**, 93%**5b**, 94%**5c**, 93%**5d**, 92%**5e**, 83%**5f**, 65%**5g**, 88%**5h**, 85%**5i**, 83%

^a Reaction conditions: compound 1 (1 mmol), cyclic ethers 4 (1.5 mmol), POCl₃ (1.5 mmol), DBU (2 mmol), xylene (3 mL), 110 °C, 15 h

To gain a mechanistic insight into this method, control experiments were performed. When POCl₃ and DBU were employed, the reaction successfully produced phosphoramidic dichloride **6**, while employment of POCl₃ alone or employment of DBU alone did not yield the phosphoramidic dichloride. Besides, the controlled experiment using the prepared phosphoramidic dichloride was performed. It was found that the reaction of the prepared phosphoramidic dichloride **6** with THF under the same condition produced the corresponding

product successfully. Thus, a plausible reaction pathway based on our results can be proposed, as shown in Scheme 4. The initial addition of POCl_3 and DBU to arylamine **1** probably affords phosphoramidic dichloride **6**. Then, THF reacts with phosphoramidic dichloride **6** to provide **7**. Intramolecular attack of the nitrogen on the carbon near phosphorus atom gives the desired product, 1-phenyl-pyrrolidine **3a**.



Scheme 4. Proposed reaction mechanism for N-heterocyclization from arylamine.

CONCLUSION

In summary, a novel metal-free method for the synthesis of *N*-aryl-substituted azacycles from arylamines and cyclic ethers has been developed. In the present study, the combination of POCl_3 and DBU is crucial to produce the desired products. Using this method, *N*-aryl substituted five- and six-membered azacycles were prepared in high yields. Moreover, the reaction protocol is

1
2
3
4 simple and efficient. We expect that this novel method will be useful for the synthesis of a
5
6 variety of five- and six-membered azacycles from cyclic ethers.
7
8
9

10 11 **Experimental section**

12 13 **General Information**

14
15 All reactions were performed in 20-mL vials with Teflon caps. Commercial chemicals and
16
17 solvents were used without any purification. Reaction progress was analyzed by thin-layer
18
19 chromatography (TLC) using silica gel 60 F254 pre-coated aluminum plate from Merck and
20
21 TLC spots were observed under UV light (254nm) exposure. Flash chromatography was carried
22
23 out using 230–400 mesh silica gel and analytical grade solvents. Stuart SMP10 Melting Point
24
25 Apparatus was used to record melting points of products. Structure elucidation by NMR (¹H and
26
27 ¹³C NMR) was performed on Bruker Avance 400 MHz spectrometer. The chemical shifts were
28
29 reported in δ units (ppm) relative to the residual protonated solvent resonance, the coupling
30
31 constants (J) quoted in Hz, and multiplicity of signals was abbreviated as follows: singlet (s);
32
33 doublet (d); doublet of doublet (dd); triplet (t); multiplet (m). The high resolution mass spectra
34
35 (HRMS) were analyzed on 6200 series TOF/6500 series Q-TOF B.08.00.
36
37
38
39
40

41 **General procedure of the synthesis of azacycles 3a-3r**

42
43 To a 20 mL vial containing a stirring mixture of aniline (**1a**) (0.093 g, 1.00 mmol) and DBU
44
45 (0.304 g, 2.00 mmol) in xylene (3 mL) was added dropwise POCl₃ (0.230 g, 1.50 mmol) at room
46
47 temperature. The mixture was then heated at 90 °C for 15 min. Tetrahydrofuran (1.6 mL, 20
48
49 mmol) were added to the reaction mixture and the vial was closed tightly with Teflon cap. The
50
51 reaction mixture was allowed to heat at 110 °C for 15 h. The reaction was cooled down to the
52
53 ambient temperature, then saturated aqueous NaHCO₃ (10 mL) and brine (10mL) were added to
54
55
56
57
58
59
60

the mixture. The aqueous mixture was extracted with Et₂O and the organic layer was dried over anhydrous sodium sulfate and subsequently concentrated under reduced pressure. The crude product was then purified by flash column chromatography on silica gel with 2% diethyl ether in *n*-hexane as eluent to afford the desired product **3a** (0.140 g, 95% yield).

1-phenylpyrrolidine (3a).^{8e} Light yellow oil (0.140 g, 95% yield); ¹H NMR (400 MHz, CDCl₃) δ 7.29 (t, *J* = 7.2 Hz, 2H), 6.72 (t, *J* = 7.2 Hz, 1H), 6.63 (d, *J* = 8.0 Hz, 2H), 3.39-3.29 (m, 4H), 2.11-2.00 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 148.0, 129.1 (2C), 115.4, 111.7 (2C), 47.6 (2C), 25.5 (2C); HRMS (ESI) *m/z* (M+H)⁺ calcd for C₁₀H₁₄N = 148.1126; found 148.1129..

*1-*p*-tolylpyrrolidine (3b)*.^{8e} White solid (0.147 g, 91% yield); m.p. 41-43 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.09 (d, *J* = 8.0 Hz, 2H), 6.56 (d, *J* = 8.0 Hz, 2H), 3.35-3.25 (m, 4H), 2.31 (s, 3H), 2.10-2.00 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 146.1, 129.6 (2C), 124.5, 111.8 (2C), 47.9 (2C), 25.4 (2C), 20.3; HRMS (ESI) *m/z* (M+H)⁺ calcd for C₁₁H₁₆N = 162.1283; found 162.1285.

1-(3-methoxyphenyl)pyrrolidine (3c).^{8e} Colorless oil (0.160 g, 90% yield); ¹H NMR (400 MHz, CDCl₃) δ 7.17 (t, *J* = 8.0 Hz, 1H), 6.27 (dd, *J* = 8.0 Hz, 2.0 Hz, 1H), 6.24 (dd, *J* = 8.0 Hz, 2.0 Hz, 1H), 6.16 (t, *J* = 2.0 Hz, 1H), 3.84 (s, 3H), 3.35-3.26 (m, 4H), 2.07-2.00 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 160.7, 149.3, 129.8, 104.9, 100.5, 97.9, 55.1, 47.7 (2C), 25.5 (2C); HRMS (ESI) *m/z* (M+H)⁺ calcd for C₁₁H₁₆NO = 178.1232; found 178.1237.

*1-(4-*tert*-butylphenyl)pyrrolidine (3d)*.⁹ White solid (0.189 g, 93% yield); m.p. 40-42 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.30 (d, *J* = 8.8 Hz, 2H), 6.58 (d, *J* = 8.8 Hz, 2H), 3.35-3.27 (m, 4H), 2.05-2.00 (m, 4H), 1.34 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 145.9, 137.9, 125.9 (2C), 111.3 (2C), 47.7 (2C), 33.7, 31.6 (3C), 25.5 (2C); HRMS (ESI) *m/z* (M+H)⁺ calcd for C₁₄H₂₂N = 204.1752; found 204.1751..

1
2
3
4 *1-(3,5-dimethylphenyl)pyrrolidine (3e)*.¹³ Colorless oil (0.137 g, 78% yield); ¹H NMR (400 MHz,
5 CDCl₃) δ 6.38 (s, 1H), 6.26 (s, 2H), 3.35-3.29 (m, 4H), 2.32 (s, 6H), 2.05-1.97 (m, 4H); ¹³C
6 NMR (100 MHz, CDCl₃) δ 148.2, 138.7 (2C), 117.5, 109.7 (2C), 47.6 (2C), 25.5 (2C), 21.7 (2C);
7
8 HRMS (ESI) m/z (M+H)⁺ calcd for C₁₂H₁₈N = 176.1439; found 176.1441..
9
10

11
12
13 *1-(2,6-diisopropylphenyl)pyrrolidine (3f)*.⁹ Colorless oil (0.146 g, 63% yield); ¹H NMR (400
14 MHz, CDCl₃) δ 7.23 (t, *J* = 7.2 Hz, 1H), 7.15 (d, *J* = 7.2 Hz, 2H), 3.36-3.20 (m, 6H), 2.11-2.00
15 (m, 4H), 1.25 (d, *J* = 6.0 Hz, 12H); ¹³C NMR (100 MHz, CDCl₃) δ 150.1, 142.9, 126.3 (2C),
16 (m, 4H), 1.25 (d, *J* = 6.0 Hz, 12H); ¹³C NMR (100 MHz, CDCl₃) δ 150.1, 142.9, 126.3 (2C),
17 123.9 (2C), 52.8 (2C), 28.0 (2C), 26.6 (2C), 24.5 (4C); HRMS (ESI) m/z (M+H)⁺ calcd for
18 C₁₆H₂₆N = 232.2065; found 232.2067.
19
20
21
22
23

24
25 *1-(4-nitrophenyl)pyrrolidine (3g)*.⁹ Yellow solid (0.162 g, 84% yield); m.p. 167-169 °C; ¹H
26 NMR (400 MHz, CDCl₃) δ 8.13 (d, *J* = 9.2 Hz, 2H), 6.49 (d, *J* = 9.2 Hz, 2H), 3.37-3.29 (m, 4H),
27 2.15-2.05 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 151.9, 136.6, 126.3 (2C), 110.4 (2C), 47.9
28 (2C), 25.4 (2C); HRMS (ESI) m/z (M+H)⁺ calcd for C₁₀H₁₃N₂O₂ = 193.0977; found 193.0978..
29
30
31
32
33

34 *1-(3-chlorophenyl)pyrrolidine (3h)*.⁹ Colorless oil (0.165 g, 91% yield); ¹H NMR (400 MHz,
35 CDCl₃) δ 7.14 (t, *J* = 8.0 Hz, 1H), 6.64 (dd, *J* = 7.6 Hz, 1.2 Hz, 1H), 6.55 (t, *J* = 2.0 Hz, 1H),
36 6.45 (dd, *J* = 8.4 Hz, 2.0 Hz, 1H), 3.32-3.25 (m, 4H), 2.07-2.00 (m, 4H); ¹³C NMR (100 MHz,
37 CDCl₃) δ 148.8, 134.9, 130.0, 115.1, 111.4, 109.8, 47.6 (2C), 25.4 (2C); HRMS (ESI) m/z
38 (M+H)⁺ calcd for C₁₀H₁₃ClN = 182.0737; found 182.0736.
39
40
41
42
43
44

45
46 *1-(4-fluorophenyl)pyrrolidine (3i)*.^{8e} Colorless oil (0.153 g, 92% yield); ¹H NMR (400 MHz,
47 CDCl₃) δ 7.03-6.93 (m, 2H), 6.55-6.47 (m, 2H), 3.33-3.20 (m, 4H), 2.10-2.00 (m, 4H); ¹³C NMR
48 (100 MHz, CDCl₃) δ 156.0&153.6 (d, ¹*J*_{C-F} = 231.8 Hz, 1C), 144.8, 115.5&115.3 (d, ²*J*_{C-F} = 21.9
49 Hz, 2C), 112.1&112.0 (d, ³*J*_{C-F} = 4.6 Hz, 2C), 48.1 (2C), 25.5 (2C); HRMS (ESI) m/z (M+H)⁺
50 calcd for C₁₀H₁₃FN = 166.1032; found 166.1037.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 *1-(2,4-difluorophenyl)pyrrolidine (3j)*.^{8e} Colorless oil (0.166 g, 90% yield); ¹H NMR (400 MHz,
5 CDCl₃) δ 6.85-6.72 (m, 2H), 6.70-6.59 (m, 1H), 3.30-3.20 (m, 4H), 2.07-1.90 (m, 4H); ¹³C NMR
6 (100 MHz, CDCl₃) δ 156.0-153.5 (dd, ¹J_{C-F} = 238.3 Hz, ³J_{C-F} = 12.4 Hz, 1C), 153.1-150.5 (dd,
7 ¹J_{C-F} = 243.4 Hz, ³J_{C-F} = 10.9 Hz, 1C), 134.3, 115.2, 110.5&110.3 (d, ²J_{C-F} = 18.2 Hz, 1C), 104.7-
8 104.2 (t, ²J_{C-F} = 25.5 Hz, 1C), 50.0 (2C), 25.0 (2C); HRMS (ESI) m/z (M+H)⁺ calcd for
9 C₁₀H₁₂F₂N = 184.0938; found 184.0940.

10
11
12
13
14
15
16
17
18 *1-(naphthalen-1-yl)pyrrolidine (3k)*.^{8e} Light yellow oil (0.182 g, 92% yield); ¹H NMR (400 MHz,
19 CDCl₃) δ 8.29-8.22 (m, 1H), 7.88-7.82 (m, 1H), 7.52-7.45 (m, 3H), 7.40 (t, *J* = 7.6 Hz, 1H), 7.01
20 (d, *J* = 7.6 Hz, 1H), 3.48-3.38 (m, 4H), 2.12-2.02 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 147.7,
21 135.0, 128.3, 128.2, 125.9, 125.5, 124.8, 124.3, 121.3, 111.4, 52.7 (2C), 24.8 (2C); HRMS (ESI)
22 m/z (M+H)⁺ calcd for C₁₄H₁₆N = 198.1283; found 198.1284.

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
1-(benzo[d][1,3]dioxol-5-yl)pyrrolidine (3l).¹⁴ Light yellow solid (0.157 g, 82% yield); m.p. 68-
70 °C; ¹H NMR (400 MHz, CDCl₃) δ 6.74 (d, *J* = 8.4 Hz, 1H), 6.25 (d, *J* = 1.6 Hz, 1H), 5.99 (d,
41 *J* = 7.2 Hz, 1H), 5.87 (s, 2H), 3.30-3.20 (m, 4H), 2.07-1.97 (m, 4H); ¹³C NMR (100 MHz, CDCl₃)
42 δ 148.3, 144.5, 138.1, 108.7, 103.0, 100.4, 94.5, 48.4 (2C), 25.4 (2C); HRMS (ESI) m/z (M+H)⁺
43 calcd for C₁₁H₁₄NO₂ = 192.1025; found 192.1028.

44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyrrolidine (3m).¹⁵ Yellowish oil (0.165 g, 80% yield);
¹H NMR (400 MHz, CDCl₃) δ 6.79 (dd, *J* = 9.2 Hz, *J* = 3.2 Hz, 1H), 6.14 (d, *J* = 6.8 Hz, 2H),
4.28 – 4.20 (m, 4H), 3.22(t, *J* = 6.8 Hz, 4H), 2.01 -1.96 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ
143.94, 143.73, 117.51, 105.42, 105.23, 100.36, 64.86, 64.24, 48.14 (2C), 25.38 (2C); HRMS
(ESI) m/z (M+H)⁺ calcd for C₁₂H₁₆NO₂ = 206.1181; found 206.1182.

N,N-dimethyl-4-(pyrrolidin-1-yl)aniline (3n).¹⁶ White solid (0.145 g, 76% yield); m.p. 68-70 °C
¹H NMR (400 MHz, (CD₃)₂CO) δ 6.73 (d, *J* = 8.8 Hz, 2H), 6.49 (d, *J* = 8.5 Hz, 2H), 3.30-3.00

(m, 4H), 2.75 (s, 6H), 1.97-1.91 (m, 4H); ^{13}C NMR (100 MHz, $(\text{CD}_3)_2\text{CO}$) δ 142.84, 141.74, 115.69 (2C), 112.71 (2C), 47.85 (2C), 41.50 (2C), 24.95 (2C); HRMS (ESI) m/z ($\text{M}+\text{H}$) $^+$ calcd for $\text{C}_{12}\text{H}_{19}\text{N}_2 = 191.1548$; found 191.1547.

2-(pyrrolidin-1-yl)pyridine (3o).¹⁷ Yellow oil (0.082 g, 55% yield); ^1H NMR (400 MHz, CDCl_3) δ 8.17 (d, $J = 4.8$ Hz, 1H), 7.48-7.41 (m, 1H), 6.52 (t, $J = 6.0$ Hz, 1H), 6.36 (d, $J = 8.4$ Hz, 1H), 3.50-3.40 (m, 4H), 2.09-2.00 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.2, 148.1, 136.9, 111.0, 106.5, 46.6 (2C), 25.5 (2C); HRMS (ESI) m/z ($\text{M}+\text{H}$) $^+$ calcd for $\text{C}_9\text{H}_{13}\text{N}_2 = 149.1079$; found 149.1080.

2-methyl-1-phenylpyrrolidine (3p).^{8e} Light yellow oil (0.151 g, 93% yield); ^1H NMR (400 MHz, CDCl_3) δ 7.30-7.23 (m, 2H), 6.84 (t, $J = 8.8$ Hz, 1H), 6.63 (d, $J = 8.0$ Hz, 2H), 3.96-3.87 (m, 1H), 3.51-3.43 (m, 1H), 3.25-3.16 (m, 1H), 2.19-1.97 (m, 3H), 1.79-1.70 (m, 1H), 1.22 (d, $J = 6.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 147.2, 129.2 (2C), 115.1, 111.8 (2C), 53.6, 48.2, 33.1, 23.3, 19.4; HRMS (ESI) m/z ($\text{M}+\text{H}$) $^+$ calcd for $\text{C}_{11}\text{H}_{16}\text{N} = 162.1283$; found 162.1285.

2-methyl-1-p-tolylpyrrolidine (3q).^{8e} Colorless oil (0.159 g, 90% yield); ^1H NMR (400 MHz, CDCl_3) δ 7.06 (d, $J = 6.4$ Hz, 2H), 6.55 (d, $J = 6.0$ Hz, 2H), 3.90-3.80 (m, 1H), 3.47-3.38 (m, 1H), 3.23-3.10 (m, 1H), 2.28 (s, 3H), 2.15-1.95 (m, 3H), 1.75-1.65 (m, 1H), 1.20 (d, $J = 5.6$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 145.3, 129.7 (2C), 124.2, 111.9 (2C), 53.7, 48.5, 33.2, 23.4, 20.3, 19.5; HRMS (ESI) m/z ($\text{M}+\text{H}$) $^+$ calcd for $\text{C}_{12}\text{H}_{18}\text{N} = 176.1439$; found 176.1438.

1-(4-chlorophenyl)-2-methylpyrrolidine (3r).⁹ White solid (0.167 g, 85% yield); m.p. 41-43 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.15 (d, $J = 8.8$ Hz, 2H), 6.51 (t, $J = 6.0$ Hz, 2H), 3.90-3.80 (m, 1H), 3.47-3.38 (m, 1H), 3.23-3.10 (m, 1H), 2.28 (s, 3H), 2.15-1.95 (m, 3H), 1.75-1.65 (m, 1H), 1.20 (d, $J = 5.6$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 145.7, 128.9 (2C), 119.9, 112.8 (2C),

53.8, 48.3, 33.1, 23.3, 19.1; HRMS (ESI) m/z (M+H)⁺ calcd for C₁₁H₁₅ClN = 196.0893; found 196.0894.

2-methyl-1-(naphthalen-1-yl)pyrrolidine (3s).¹⁸ Light yellow oil (0.176 g, 83% yield); ¹H NMR (400 MHz, CDCl₃) δ 8.30-8.25 (m, 1H), 7.88-7.82 (m, 1H), 7.55-7.40 (m, 4H), 7.07 (t, J = 7.6 Hz, 1H), 3.92-3.75 (m, 2H), 3.00-2.90 (m, 1H), 2.32-2.13 (m, 1H), 2.10-2.00 (m, 1H), 1.95-1.82 (m, 1H), 1.80-1.70 (m, 1H), 1.11 (d, J = 5.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 146.9, 134.8, 130.1, 128.1, 125.8, 125.6, 124.7, 124.5, 122.0, 114.1, 55.7, 55.4, 33.6, 23.5, 18.7; HRMS (ESI) m/z (M+H)⁺ calcd for C₁₅H₁₈N = 212.1439; found 212.1437.

1-phenylpiperidine (3t).⁹ Colorless oil (0.105 g, 65% yield); ¹H NMR (400 MHz, CDCl₃) δ 7.33-7.24 (m, 2H), 6.98 (d, J = 7.6 Hz, 2H), 6.86 (t, J = 7.2 Hz, 1H), 3.30-3.15 (m, 4H), 1.85-1.72 (m, 4H), 1.68-1.55 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 152.3, 129.0 (2C), 119.2, 116.6 (2C), 50.7 (2C), 25.9 (2C), 24.3; HRMS (ESI) m/z (M+H)⁺ calcd for C₁₁H₁₆N = 162.1283; found 162.1283.

1-phenylazepane (3u).¹⁹ Light yellow oil (0.111 g, 63% yield); ¹H NMR (400 MHz, CDCl₃) δ 7.28-7.20 (m, 2H), 6.72 (d, J = 8.0 Hz, 2H), 6.64 (t, J = 7.2 Hz, 1H), 3.47 (t, J = 9.2 Hz, 4H), 1.85-1.75 (m, 4H), 1.59-1.55 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 148.86, 129.24 (2C), 115.08, 111.17 (2C), 49.04 (2C), 27.79 (2C), 27.17 (2C); HRMS (ESI) m/z (M+H)⁺ calcd for C₁₂H₁₈N = 176.1439; found 176.1440.

4-phenylmorpholine (3v).²⁰ Light brown solid (0.093 g, 57% yield); m.p. 52-54 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.38-7.28 (m, 2H), 7.03-6.90 (m, 3H), 3.90 (t, J = 4.4 Hz, 4H), 3.19 (t, J = 4.8 Hz, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 151.2, 129.2 (2C), 120.1, 115.7 (2C), 67.0 (2C), 49.4 (2C); HRMS (ESI) m/z (M+H)⁺ calcd for C₁₀H₁₄NO = 164.1075; found 164.1078.

General procedure of the synthesis of azacycles **5a-5e**

To a 20 mL vial containing a stirring mixture of aniline (**1a**) (0.093 g, 1.00 mmol) and DBU (0.304 g, 2.00 mmol) in xylene (3 mL) was added dropwise POCl₃ (0.230 g, 1.50 mmol) at room temperature. The mixture was then heated at 90 °C for 15 min. Phthalan (0.180 g, 1.50 mmol) was added to the reaction mixture and the vial was closed tightly with Teflon cap. The reaction mixture was allowed to heat at 110 °C for 15 h. The reaction was cooled down to the ambient temperature, then saturated aqueous NaHCO₃ (10 mL) and brine (10mL) were added to the mixture. The aqueous mixture was extracted with Et₂O and the organic layer was dried over anhydrous sodium sulfate and subsequently concentrated under reduced pressure. The crude product was then purified by flash column chromatography on silica gel with 2% diethyl ether in *n*-hexane as eluent to afford the desired product **5a** (0.181 g, 93% yield).

2-phenylisoindoline (5a).^{8e} White solid (0.181 g, 93% yield); m.p. 171-173 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.32 (m, 6H), 6.80 (t, *J* = 7.2 Hz, 1H), 6.73 (d, *J* = 8.0 Hz, 2H), 4.70 (s, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 147.1, 137.9 (2C), 129.4 (2C), 127.2 (2C), 122.6 (2C), 116.2, 111.4 (2C), 53.8 (2C); HRMS (ESI) *m/z* (M+H)⁺ calcd for C₁₄H₁₄N = 196.1126; found 196.1129.

2-p-tolylisoindoline (5b).²¹ White solid (0.197 g, 94% yield); m.p. 196-198 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.30 (m, 4H), 7.16 (d, *J* = 8.4 Hz, 2H), 6.66 (d, *J* = 8.4 Hz, 2H), 4.67 (s, 4H), 2.34 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 145.2, 138.1 (2C), 129.9 (2C), 127.1 (2C), 125.3, 122.6 (2C), 111.7 (2C), 54.0 (2C), 20.3; HRMS (ESI) *m/z* (M+H)⁺ calcd for C₁₅H₁₆N = 210.1283; found 210.1285.

2-(4-chlorophenyl)isoindoline (5c).^{8e} White solid (0.214 g, 93% yield); m.p. 170-172 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.30 (m, 4H), 7.26 (d, *J* = 9.2 Hz, 2H), 6.61 (d, *J* = 8.8 Hz, 2H), 4.65 (s, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 145.7, 137.6 (2C), 129.2 (2C), 127.3 (2C), 122.6

(2C), 121.1, 112.6 (2C), 53.9 (2C); HRMS (ESI) m/z (M+H)⁺ calcd for C₁₄H₁₃ClN = 230.0737; found 230.0738.

2-(4-nitrophenyl)isoindoline (5d).²² Yellow solid (0.222 g, 92% yield); m.p. 266-268 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.23 (d, J = 9.2 Hz, 2H), 7.43-7.35 (m, 4H), 6.64 (d, J = 9.2 Hz, 2H), 4.80 (s, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 151.3, 137.5, 136.3 (2C), 127.8 (2C), 126.4 (2C), 122.7 (2C), 110.5 (2C), 54.0 (2C); HRMS (ESI) m/z (M+H)⁺ calcd for C₁₄H₁₃N₂O₂ = 241.0977; found 241.0975.

2-(2,6-dimethylphenyl)isoindoline (5e).²³ White solid (0.186 g, 83% yield); m.p. 60-62 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.30 (m, 4H), 7.15-7.05 (m, 3H), 4.69 (s, 4H), 2.32 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 145.1, 140.1 (2C), 138.9 (2C), 128.7 (2C), 126.7 (2C), 126.9, 122.5 (2C), 57.2 (2C), 18.7 (2C); HRMS (ESI) m/z (M+H)⁺ calcd for C₁₆H₁₈N = 224.1439; found 224.1438.

General procedure of the synthesis of azacycles **5f-5i**

To a 20 mL vial containing a stirring mixture of aniline (**1a**) (0.093 g, 1.00 mmol) and DBU (0.304 g, 2.00 mmol) in xylene (3 mL) was added dropwise POCl₃ (0.230 g, 1.50 mmol) at room temperature. The mixture was then heated at 90 °C for 15 min. Isochroman (0.201 g, 1.50 mmol) was added to the reaction mixture and the vial was closed tightly with Teflon cap. The reaction mixture was allowed to heat at 110 °C for 15 h. The reaction was cooled down to the ambient temperature, then saturated aqueous NaHCO₃ (10 mL) and brine (10 mL) were added to the mixture. The aqueous mixture was extracted with Et₂O and the organic layer was dried over anhydrous sodium sulfate and subsequently concentrated under reduced pressure. The crude product was then purified by flash column chromatography on silica gel with 2% diethyl ether in *n*-hexane as eluent to afford the desired product **5f** (0.136 g, 65% yield).

1
2
3
4 *2-phenyl-1,2,3,4-tetrahydroisoquinoline (5f)*.^{8e} White solid (0.136 g, 65% yield); m.p. 45-47 °C;
5
6 ¹H NMR (400 MHz, CDCl₃) δ 7.37-7.31 (m, 2H), 7.26-7.18 (m, 4H), 7.03 (d, *J* = 8.0 Hz, 2H),
7
8 6.89 (t, *J* = 7.6 Hz, 1H), 4.46 (s, 2H), 3.61 (t, *J* = 6.0 Hz, 2H), 3.03 (t, *J* = 5.6 Hz, 2H); ¹³C NMR
9
10 (100 MHz, CDCl₃) δ 150.5, 134.9, 134.4, 129.2 (2C), 128.5, 126.5, 126.3, 126.0, 118.7, 115.2
11
12 (2C), 50.8, 46.6, 29.1; HRMS (ESI) *m/z* (M+H)⁺ calcd for C₁₅H₁₆N = 210.1283; found 210.1284.

13
14
15
16 *2-(4-chlorophenyl)-1,2,3,4-tetrahydroisoquinoline (5g)*.^{8e} White solid (0.215 g, 88% yield); m.p.
17
18 69-71 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.30-7.25 (m, 6H), 6.91 (d, *J* = 9.2 Hz, 2H), 4.41 (s,
19
20 2H), 3.56 (t, *J* = 6.0 Hz, 2H), 3.01 (t, *J* = 6.0 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 149.0,
21
22 134.7, 134.0, 129.0 (2C), 128.5, 126.5 (2C), 126.1, 123.4, 116.2 (2C), 50.7, 46.5, 28.9; HRMS
23
24 (ESI) *m/z* (M+H)⁺ calcd for C₁₅H₁₅ClN = 244.0893; found 244.0895..

25
26
27 *2-(2,4-difluorophenyl)-1,2,3,4-tetrahydroisoquinoline (5h)*.^{8e} White solid (0.209 g, 85% yield);
28
29 m.p. 85-87 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.25-7.15 (m, 3H), 7.15-7.10 (m, 1H), 7.05-6.96
30
31 (m, 1H), 6.92-6.78 (m, 2H), 4.29 (s, 2H), 3.42 (t, *J* = 5.6 Hz, 2H), 3.02 (t, *J* = 6.0 Hz, 2H); ¹³C
32
33 NMR (100 MHz, CDCl₃) δ 159.1-156.9 (dd, ¹*J*_{C-F} = 211.4 Hz, ³*J*_{C-F} = 11.6 Hz, 1C), 156.8-154.4
34
35 (dd, ¹*J*_{C-F} = 217.3 Hz, ³*J*_{C-F} = 11.7 Hz, 1C), 136.4&136.3 (d, ³*J*_{C-F} = 8.8 Hz, 1C), 134.2 (2C),
36
37 128.9, 126.4, 126.3, 125.9, 120.1&120.0 (d, ³*J*_{C-F} = 5.1 Hz, 1C), 110.8-110.5 (dd, ²*J*_{C-F} = 21.1 Hz,
38
39 ⁴*J*_{C-F} = 3.6 Hz, 1C), 105.0-104.5 (t, ²*J*_{C-F} = 25.5 Hz, 1C), 53.1, 49.3 (d, ⁴*J*_{C-F} = 3.7 Hz, 1C), 28.8;
40
41 HRMS (ESI) *m/z* (M+H)⁺ calcd for C₁₅H₁₄F₂N = 246.1094; found 246.1097.

42
43
44
45
46 *2-(3,5-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline (5i)*.²⁴ White solid (0.197 g, 83% yield);
47
48 m.p. 49-51 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.25-7.15 (m, 4H), 6.67 (s, 2H), 6.55 (s, 1H), 4.43
49
50 (s, 2H), 3.57 (t, *J* = 5.6 Hz, 2H), 3.02 (t, *J* = 6.0 Hz, 2H), 2.35 (s, 6H); ¹³C NMR (100 MHz,
51
52 CDCl₃) δ 150.8, 138.7 (2C), 134.9, 134.6, 128.5, 126.5, 126.3, 126.0, 120.8, 113.2 (2C), 51.0,
53
54 46.7, 29.3, 21.8 (2C); HRMS (ESI) *m/z* (M+H)⁺ calcd for C₁₇H₂₀N = 238.1596; found 238.1597.
55
56
57
58
59
60

1
2
3
4 *Phenylphosphoramidic dichloride (6)*.²⁵ To a 20 mL vial containing a stirring mixture of aniline
5
6
7 (**1a**) (0.093 g, 1.00 mmol) and DBU (0.304 g, 2.00 mmol) in xylene (3 mL) was added dropwise
8
9 POCl₃ (0.230 g, 1.50 mmol) at room temperature. The mixture was then stirred at 90 °C for 30
10
11 min, quenched with saturated ammonium chloride, and extracted with CH₂Cl₂ (2 × 10 mL). The
12
13 organic layer was dried over sodium sulfate and concentrated under reduced pressure. The
14
15 resulting residue was then purified by flash column chromatography on silica gel with hexane-
16
17 EtOAc as eluent to afford the desired product **6** (0.178 g, 85%). White solid (0.178 g, 85% yield);
18
19 m.p. 80-82 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.39 (t, *J* = 8.4 Hz, 2H), 7.27-7.20 (m, 3H), 7.11-
20
21 7.00 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 136.3, 129.7 (2C), 125.2, 121.1 (2C); ³¹P NMR
22
23 (CDCl₃) δ 8.43; HRMS (ESI) *m/z* (M+H)⁺ calcd for C₆H₇Cl₂NOP = 209.9642; found 209.9645.
24
25
26
27
28

29 ASSOCIATED CONTENT

30 Supporting Information

31
32 The Supporting Information is available free of charge on the ACS Publications website at DOI:
33
34 ¹H and ¹³C NMR spectra of compounds **3a-3v**, **5a-5i**, and **6**. Screening of reaction conditions for
35
36 the preparation of azacycles the products (PDF)
37
38
39
40
41
42

43 AUTHOR INFORMATION

44 Corresponding Author

45
46
47 * *E-mail address*: hkkim717@jbnu.ac.kr (H-K Kim).
48
49

50 ORCID

51
52 Minh Thanh La: 0000-0001-9280-1769
53

54
55 Soosung Kang: 0000-0001-7016-2417
56
57
58
59
60

1
2
3
4 Hee-Kwon Kim: 0000-0001-7612-7049
5
6
7

8 9 **Notes**

10
11 The authors declare no competing financial interest.
12
13

14 15 **ACKNOWLEDGMENT**

16
17
18 This research was supported by Basic Science Research Program through the National Research
19
20 Foundation of Korea (NRF) funded by the Ministry of Education (2018R1D1A1B07047572).
21
22
23

24 25 **REFERENCES**

- 26
27 (1) (a) Ciufolini, M. A.; Hermann, C. W.; Whitmire, K. H.; Byrne, N. E. Chemoenzymatic
28
29 preparation of trans-2,6-dialkylpiperidines and of other azacycle building blocks. Total synthesis
30
31 of (+)-desoxoprosopinine. *J. Am. Chem. Soc.* **1989**, *111*, 3473-3475; (b) Lu, X.; Peng, Y.; Wang,
32
33 C.; Yang, J.; Bao, X.; Dong, Q.; Zhao, W.; Tan, W.; Dong, X. Design, synthesis, and biological
34
35 evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitors. *Eur.*
36
37 *J. Med. Chem.* **2017**, *138*, 384-395; (c) Wang, C.; Zhu, M.; Lu, X.; Wang, H.; Zhao, W.; Zhang,
38
39 X.; Dong, X. Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog
40
41 signaling pathway inhibitors. *Bioorganic Med. Chem.* **2018**, *26*, 3308-3320; (d) Marsh, J. D.;
42
43 Smith, T. W. Piretanide: a loop-active diuretic. *Pharmacotherapy* **1984**, *4*, 170-178; (e) Hussein,
44
45 Z.; Mulford, D. J.; Bopp, B. A.; Granneman, G. R. Stereoselective pharmacokinetics of
46
47 pazinaclone, a new non-benzodiazepine anxiolytic, and its active metabolite in healthy subjects.
48
49 *Br. J. Clin. Pharmacol.* **1993**, *36*, 357-361; (f) Zhanel, G. G.; Walkty, A.; Vercaigne, L.;
50
51 Karlowsky, J. A.; Embil, J.; Gin, A. S.; Hoban, D. J. The new fluoroquinolones: a critical review.
52
53
54
55
56
57
58
59
60

1
2
3
4 *Can. J. Infect. Dis.* **1999**, *10*, 207-238.

6 (2) (a) Hubbard, H.; Lawitz, E. Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the
7 treatment of hepatitis C. *Expert Rev Gastroenterol Hepatol* **2018**, *12*, 9-17; (b) Popovici-Muller,
8 J.; Lemieux, R. M.; Artin, E.; Saunders, J. O.; Salituro, F. G.; Travins, J.; Cianchetta, G.; Cai, Z.;
9 Zhou, D.; Cui, D.; Chen, P.; Straley, K.; Tobin, E.; Wang, F.; David, M. D.; Penard-Lacronique,
10 V.; Quivoron, C.; Saada, V.; de Botton, S.; Gross, S.; Dang, L.; Yang, H.; Utley, L.; Chen, Y.;
11 Kim, H.; Jin, S.; Gu, Z.; Yao, G.; Luo, Z.; Lv, X.; Fang, C.; Yan, L.; Olaharski, A.; Silverman,
12 L.; Biller, S.; Su, S.-S. M.; Yen, K. Discovery of AG-120 (Ivosidenib): a first-in-class mutant
13 IDH1 inhibitor for the treatment of IDH1 mutant cancers. *ACS Med. Chem. Lett.* **2018**, *9*, 300-
14 305; (c) Vangapandu, H. V.; Jain, N.; Gandhi, V. Duvelisib: a phosphoinositide-3 kinase δ/γ
15 inhibitor for chronic lymphocytic leukemia. *Expert Opin. Investig. Drugs* **2017**, *26*, 625-632; (d)
16 Camidge, D. R.; Kim, H. R.; Ahn, M.-J.; Yang, J. C.-H.; Han, J.-Y.; Lee, J.-S.; Hochmair, M. J.;
17 Li, J. Y.-C.; Chang, G.-C.; Lee, K. H.; Gridelli, C.; Delmonte, A.; Garcia Campelo, R.; Kim, D.-
18 W.; Bearz, A.; Griesinger, F.; Morabito, A.; Felip, E.; Califano, R.; Ghosh, S.; Spira, A.;
19 Gettinger, S. N.; Tiseo, M.; Gupta, N.; Haney, J.; Kerstein, D.; Popat, S. Brigatinib versus
20 Crizotinib in ALK-positive non-small-cell lung cancer. *N. Engl. J. Med.* **2018**, *379*, 2027-2039;
21 (e) Perl, A. E.; Altman, J. K.; Cortes, J.; Smith, C.; Litzow, M.; Baer, M. R.; Claxton, D.; Erba,
22 H. P.; Gill, S.; Goldberg, S.; Jurcic, J. G.; Larson, R. A.; Liu, C.; Ritchie, E.; Schiller, G.; Spira,
23 A. I.; Strickland, S. A.; Tibes, R.; Ustun, C.; Wang, E. S.; Stuart, R.; Röllig, C.; Neubauer, A.;
24 Martinelli, G.; Bahceci, E.; Levis, M. Selective inhibition of FLT3 by gilteritinib in relapsed or
25 refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study.
26 *Lancet Oncol.* **2017**, *18*, 1061-1075.

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54 (3) (a) Craig, L. C.; Hixon, R. M. Synthesis of *N*-phenylpyrrolidine and *N*-
55
56
57
58
59
60

1
2
3
4 hexahydrophenylpyrrolidine. *J. Am. Chem. Soc.* **1930**, *52*, 804-808; (b) Cui, X.; Dai, X.; Deng,
5
6 Y.; Shi, F. Development of a general non-noble metal catalyst for the benign amination of
7
8 alcohols with amines and ammonia. *Chem. Eur. J.* **2013**, *19*, 3665-3675.

9
10
11 (4) (a) Collins, C. J.; Lanz, M.; Singaram, B. Facile reduction of tertiary lactams to cyclic
12
13 amines with 9-borabicyclo[3.3.1]nonane (9-BBN). *Tetrahedron Lett.* **1999**, *40*, 3673-3676; (b)
14
15 Shim, S. C.; Huh, K. T.; Park, W. H. A new and facile synthesis of n-substituted pyrrolidine of
16
17 amines with aqueous succinaldehyde using tetracarbonylhydridoferrate, $\text{HFe}(\text{CO})_4^-$, as a highly
18
19 selective reducing agent. *Tetrahedron* **1986**, *42*, 259-263; (c) Watanabe, Y.; Shim, S. C.; Uchida,
20
21 H.; Mitsudo, T.; Takegami, Y. The reductive amination of phthalaldehyde by
22
23 tetracarbonylhydridoferrate: Synthesis of 2-arylisoindoles. *Tetrahedron* **1979**, *35*, 1433-1436.

24
25
26
27 (5) (a) Rout, L.; Jammi, S.; Punniyamurthy, T. Novel CuO nanoparticle catalyzed C–N cross
28
29 coupling of amines with iodobenzene. *Org. Lett.* **2007**, *9*, 3397-3399; (b) Khatri, P. K.; Jain, S.
30
31 L. Glycerol ingrained copper: an efficient recyclable catalyst for the N-arylation of amines with
32
33 aryl halides. *Tetrahedron Lett.* **2013**, *54*, 2740-2743.

34
35
36 (6) Jeffrey, J. L.; Bartlett, E. S.; Sarpong, R. Intramolecular C(sp³)-N coupling by oxidation
37
38 of benzylic C,N-dianions. *Angew. Chem. Int. Ed.* **2013**, *52*, 2194-2197.

39
40
41 (7) Bourns, A. N.; Embleton, H. W.; Hansuld, M. K. The reaction of tetrahydropyran with
42
43 primary aromatic amines over activated alumina. *Can. J. Chem.* **1952**, *30*, 1-8.

44
45
46 (8) (a) Walkup, R. E.; Searles, S. Synthesis of sterically hindered 1-arylpyrrolidines and 1-
47
48 arylpiperidines by condensation of primary aromatic amines with cyclic ethers or diols.
49
50 *Tetrahedron* **1985**, *41*, 101-106; (b) Olsen, C. J.; Furst, A. N-Phenylpyrrolidine¹. *J. Am. Chem.*
51
52 *Soc.* **1953**, *75*, 3026-3026; (c) Hargis, D. C.; Shubkin, R. L. gem-cyclodialkylation A facile
53
54 synthetic route to N-substituted heterocycles. *Tetrahedron Lett.* **1990**, *31*, 2991-2994; (d) Sun,
55
56
57
58
59
60

1
2
3
4 Z.; Hu, S.; Huo, Y.; Wang, Z. Titanium tetrachloride-mediated synthesis of N-aryl-substituted
5 azacycles from cyclic ethers. *RSC Adv.* **2017**, *7*, 4363-4367; (e) Korbadi, B. L.; Lee, S.-H.
6
7 Synthesis of N-aryl substituted, five- and six-membered azacycles using aluminum-amide
8
9 complexes. *Chem. Commun.* **2014**, *50*, 8985-8988.
10
11

12
13 (9) Zhang, Z.; Miao, C.; Xia, C.; Sun, W. Synergistic acid-catalyzed synthesis of N-aryl-
14 substituted azacycles from anilines and cyclic ethers. *Org. Lett.* **2016**, *18*, 1522-1525.
15
16

17
18 (10) (a) Hou, T.; Zhang, C.; Wang, Y.; Liu, Z.; Zhang, Z.; Wang, F. Metal-free protocol for
19 the synthesis of N-arylpiperidines catalyzed by hydrogen iodine. *Catal. Commun.* **2017**, *94*, 56-
20
21 59; (b) Hu, S.; Huo, Y.; Wang, Z. Boron trifluoride-mediated synthesis of N-aryl-substituted
22
23 piperidines from tetrahydrofuran and amines. *Chem. Heterocycl. Comp.* **2017**, *53*, 1365-1368.
24
25

26
27 (11) (a) Zwierzak, A.; Brylikowska-Piotrowicz, J. Alkylation of diethyl phosphoramidates – a
28 simple route from primary to secondary amines. *Angew. Chem. Int. Ed.* **1977**, *16*, 107-107; (b)
29
30 Ciufolini, M. A.; Spencer, G. O. Preparation of activated imines and their condensation with
31
32 allylstannanes: stereoselective synthesis of 1,2-amino alcohols. *J. Org. Chem.* **1989**, *54*, 4739-
33
34 4741; (c) Yadav, L. D. S.; Rai, A.; Rai, V. K.; Awasthi, C. Novel aziridination of α -halo ketones:
35
36 an efficient nucleophile-induced cyclization of phosphoramidates to functionalized aziridines.
37
38 *Tetrahedron Lett.* **2008**, *49*, 687-690; (d) Yadav, L. D. S.; Awasthi, C.; Rai, V. K.; Rai, A. A
39
40 convenient synthesis of 1,2,4-trisubstituted azetidines by reductive cyclization of aza-Michael
41
42 adducts of chalcones. *Tetrahedron Lett.* **2007**, *48*, 8037-8039.
43
44
45

46
47 (12) (a) Holzer, P.; Masuya, K.; Furet, P.; Kallen, J.; Valat-Stachyra, T.; Ferretti, S.;
48
49 Berghausen, J.; Bouisset-Leonard, M.; Buschmann, N.; Pissot-Soldermann, C.; Rynn, C.; Ruetz,
50
51 S.; Stutz, S.; Chène, P.; Jeay, S.; Gessier, F. Discovery of a dihydroisoquinolinone derivative
52
53 (NVP-CGM097): a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical
54
55
56
57
58
59
60

- 1
2
3
4 trials in p53wt tumors. *J. Med. Chem.* **2015**, *58*, 6348-6358; (b) Johnson, C. N.; Ahn, J. S.; Buck,
5 I. M.; Chiarparin, E.; Day, J. E. H.; Hopkins, A.; Howard, S.; Lewis, E. J.; Martins, V.;
6 Millemaggi, A.; Munck, J. M.; Page, L. W.; Peakman, T.; Reader, M.; Rich, S. J.; Saxty, G.;
7 Smyth, T.; Thompson, N. T.; Ward, G. A.; Williams, P. A.; Wilsher, N. E.; Chessari, G. A
8 fragment-derived clinical candidate for antagonism of X-linked and cellular inhibitor of
9 apoptosis proteins: 1-(6-[(4-fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1H,2H,3H-
10 pyrrolo[3,2-b]pyridin-1-yl)-2-[(2R,5R)-5-methyl-2-[(3R)-3-methylmorpholin-4-
11 yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660). *J. Med. Chem.* **2018**, *61*, 7314-7329; (c) Zhu,
12 K.; Song, J.-L.; Tao, H.-R.; Cheng, Z.-Q.; Jiang, C.-S.; Zhang, H. Discovery of new potent
13 protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores
14 from known inhibitors. *Bioorganic Med. Chem. Lett.* **2018**, *28*, 3693-3699; (d) Wang, A.; Huang,
15 G.; Wang, B.; Lv, K.; Wang, H.; Tao, Z.; Liu, M.; Guo, H.; Lu, Y. Design, synthesis and
16 antimycobacterial activity of 3,5-dinitrobenzamide derivatives containing fused ring moieties.
17 *Bioorganic Med. Chem. Lett.* **2018**, *28*, 2945-2948.
18
19 (13) Chen, D.; Yang, K.; Xiang, H.; Jiang, S. New ligands for copper-catalyzed C–N coupling
20 reactions with aryl halides. *Tetrahedron Lett.* **2012**, *53*, 7121-7124.
21
22 (14) Hollmann, D.; Bähn, S.; Tillack, A.; Parton, R.; Altink, R.; Beller, M. A novel salt-free
23 ruthenium-catalyzed alkylation of aryl amines. *Tetrahedron Lett.* **2008**, *49*, 5742-5745.
24
25 (15) Li, H.; Liang, W.; Wang, L.; Liu, L.; Chen, K.; Wu, Y. Convenient aqueous synthesis of N-
26 arylpyrrolidines under microwave irradiation. *Huaxue Yanjiu Yu Yingyong* **2011**, *23*, 955-960.
27
28 (16) Guizzardi, B. I.; Mella, M.; Fagnoni, M.; Albini, A. Phenonium ions from the addition of
29 phenyl cations to alkenes. Photochemical synthesis of (rearranged) aminoalkylanilines from
30 haloanilines in the presence of alkenes and amines. *J. Org. Chem.* **2003**, *68*, 1067-1074.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 (17) Zhang, Y. 1.; Yang, X.; Yao, Q.; Ma, D. CuI/DMPAO-catalyzed *N*-arylation of acyclic
5 secondary amines. *Org. Lett.* **2012**, *14*, 3056-3059.
6
7
8 (18) Afanasyev, O. I.; Tsygankov, A. A.; Usanov, D. L.; Chusov, D. Dichotomy of reductive
9 addition of amines to cyclopropyl ketones vs pyrrolidine synthesis. *Org. Lett.* **2016**, *18*, 5968-
10 5970.
11
12
13 (19) Nguyen, M. H.; Smith, A. B. Copper-catalyzed electrophilic amination of organolithiums
14 mediated by recoverable siloxane transfer agents. *Org. Lett.* **2013**, *15*, 4872-4875.
15
16 (20) Yang, Q.; Lei, X.; Yin, Z.; Deng, Z.; Peng, Y. Copper-catalyzed NaBAR₄-based *N*-arylation
17 of amines. *Synthesis*. **2019**, *51*, 538-544.
18
19 (21) Lin, C.; Zhen, L.; Cheng, Y.; Du, H. J.; Zhao, H.; Wen, X.; Kong, L. Y.; Xu, Q. L.; Sun, H.
20 Visible-light induced isoindoles formation to trigger intermolecular Diels-Alder reactions in the
21 presence of air. *Org. Lett.* **2015**, *17*, 2684-2687.
22
23 (22) Aboul-Fetouh E. Mourad, A.-F. E.; Nour-El-Din, A. M.; Hassan, A. A.; Döpp, D.
24 Charge-Transfer Complexes of Isoindolines with 1, 4-Benzoquinones. *Bulletin des Societes*
25 *Chimiques Belges*, **1986**, *95*, 1045-1051.
26
27 (23) Krejer, R. P.; Feldhoff, U.; Seubert, J.; Schmitt, D. Isoindoles and isoindolenines. Part 25. 2-
28 Aryl-2H-isoindoles. *Chemiker-Zeitung*, **1987**, *111*, 155-169.
29
30 (24) Wu, X.; Chen, D.-F.; Chen, S.-S.; Zhu, Y.-F. Synthesis of polycyclic amines through mild
31 metal-free tandem cross-dehydrogenative coupling/intramolecular hydroarylation of *N*-
32 aryltetrahydroisoquinolines and crotonaldehyde. *Eur. J. Org. Chem.* **2015**, *2015*, 458-473.
33
34 (25) MacDiarmid, J. E.; Rose, W. C.; Biddle, W. C.; Perlman, M. E.; Breiner, R. G.; Ambrus, J.
35 L.; Bardos, T. J. Synthesis and properties of bis(2,2-dimethylaziridiny)phosphinic amides: a
36 series of new antineoplastic agents. *J. Med. Chem.* **1985**, *28*, 1685-1691.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60